Lactobacillus Balances Gut Health, Improves Chronic-alcohol-induced Liver Injury

by Iswarya on  December 10, 2019 at 11:06 AM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Lactobacillus rhamnosus administration dose-dependently improved intestinal microbiome and alcohol-induced liver injury by reducing fat accumulation and the inflammatory response in the liver. The findings of the study are published in the Journal of Medicinal Food.
Lactobacillus Balances Gut Health, Improves Chronic-alcohol-induced Liver Injury
Lactobacillus Balances Gut Health, Improves Chronic-alcohol-induced Liver Injury

The article entitled "Lactobacillus rhamnosus Granules Dose-Dependently Balance Intestinal Microbiome Disorders and Ameliorate Chronic Alcohol-Induced Liver Injury" was coauthored by Yuhua Wanga and colleagues from Jilin Agricultural University, National Processing Laboratory for Soybean Industry and Technology, and National Engineering Laboratory for Wheat and Corn Deep Processing, Changchun, China.

Show Full Article


In this study, mice consumed alcohol for eight weeks and were fed Lactobacillus rhamnosus granules (LGG) the last two weeks, in varying doses (low, medium, and high) together with a high-fat diet. The researchers showed that LGG administration dose-dependently improved alcohol-induced liver injury by reducing fat accumulation and the inflammatory response in the liver. LGG consumption also ameliorated liver damage. The probiotic effect of the LGG restored a healthy balance in the gut microbiome, which was damaged by alcohol consumption. LGG reduced the number of gram-negative bacteria and increased gram-positive bacteria, including in the ileum and cecum.

"This demonstration of the impact of a probiotic intervention correcting alcohol-induced dysbiosis and reducing liver inflammation and fat accumulation has exciting potential in the prevention and treatment of alcohol-induced liver disease as well as non-alcoholic fatty liver disease," states Journal of Medicinal Food Editor-in-Chief Michael Zemel, Ph.D., Professor Emeritus, The University of Tennessee and Chief Scientific Officer, NuSirt Biopharma.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

Diabetes Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive